Dr. Parker is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
One MedImmune Way
Gaithersburg, MD 20878Phone+1 202-782-6205
Education & Training
- National Capital ConsortiumFellowship, Pulmonary Disease and Critical Care Medicine, 1993 - 1994
- National Capital ConsortiumFellowship, Pulmonary Disease and Critical Care Medicine, 1991 - 1993
- National Capital ConsortiumResidency, Internal Medicine, 1988 - 1991
- UniforMed Services University of the Health Sciences F. Edward Hebert School of MedicineClass of 1988
Certifications & Licensure
- MD State Medical License 1990 - 2025
Clinical Trials
- A Phase 2 Study to Evaluate the Safety and Efficacy of Intravenously Administered Benralizumab (MEDI-563). Start of enrollment: 2009 Feb 02
- D2212C00002 J-Phase II Study Start of enrollment: 2014 Jan 01
Publications & Presentations
PubMed
- 100 citationsSafety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies...Joseph M. Parker, Chad K. Oh, Craig LaForce, S. David Miller, David S. Pearlman
BMC Pulmonary Medicine. 2011-02-28 - 10 citationsElectron paramagnetic resonance analysis of transferrin-bound iron in animal models of blunt trauma.Nikolai V. Gorbunov, Jayasree Nath, Joseph M. Parker, Gary M. Zaucha
The Journal of Trauma. 2003-03-01 - 155 citationsMolecular and clinical rationale for therapeutic targeting of interleukin‐5 and its receptorNestor A. Molfino, David Gossage, Roland Kolbeck, Joseph M. Parker, Gregory P. Geba
Clinical and Experimental Allergy. 2012-05-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: